
Dezima gets rights to Mitsubishi Tanabe's cholesterol drug
Executive Summary
Mitsubishi Tanabe Pharma Corp. licensed Dezima Pharma BV rights to develop its Phase I dyslipidemia candidate TA8995.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
- Reverse Licensing
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com